GlassScriptPhysician profile
Kara White
NPI 1114529492
$4,471.62
in general payments reported to CMS, 2019-2025
18 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $411 · 2023: $1,034 · 2024: $1,628 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,008.23 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $700.20 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $565.89 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $358.86 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $342.31 | 2022-2024 | |
| Pfizer INC. | $316.72 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $282.20 | 2022-2025 | Nuzyra |
| Novo Nordisk INC | $173.31 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $163.14 | 2021-2022 | |
| Alkermes, INC. | $126.96 | 2024-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $125.78 | 2024-2025 | Fanapt, Hetlioz |
| Xeris Pharmaceuticals, INC. | $98.18 | 2024-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.21 | 2023-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $40.30 | 2024 | Auvelity |
| Philips North America LLC | $38.90 | 2024 | (Ck7) Extended Holter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $26.82 | 2023 | Ingrezza |
| Glaxosmithkline, LLC. | $17.21 | 2024 | Trelegy Ellipta |
| Bausch Health US, LLC | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.